Blog

April 22, 2021April 20, 2021

opti 2022: Commercial Driving Force and Platform for the Future

The next opti will be held from January 14^th to 16^th, 2022. Exhibitors can register for the trade show in Munich right away, doing so entirely free of risk but with the prospect of important and valuable business opportunities.

Bettina Reiter, exhibition director of opti, the international trade show for optics and design, along with Klaus Plaschka, managing director of GHM Gesellschaft für Handwerksmessen mbH, in their capacity as organisers, reveal in an interview why in future, trade fairs will be more important than ever, what the industry can expect from opti 2022 and why the venue in Munich will be a business booster.

See the full interview HERE.

April 21, 2021April 21, 2021

HOYA to Release Results of MiYOSMART Clinical Study at Symposium on Myopia Management

HOYA Vision Care announced they will hold their symposium on Myopia Management on 24 April 2021 where the results of a three-year clinical follow-up study on the MiYOSMART lens will be discussed. The virtual event, focusing on HOYA’s approach to managing the ever-increasing rise of myopia in children, will be held during the European Academy of Optometry and Optics (EAOO) Helsinki 2021.

The key highlight of the symposium will include HOYA Vision Care experts presenting the findings of a three-year clinical study recently published in the British Journal of Ophthalmology featuring the results of its award-winning MiYOSMART spectacle lens use with children. This study, conducted by the Centre for Myopia Research at the Hong Kong Polytechnic University and follows- up on a two-year study which previously demonstrated strong evidence of the lenses’ effectiveness in slowing down the progression of myopia in children ages 8-13 on average by 60%.

“The results of the three-year follow-up study on the MiYOSMART lens are very positive with the lens continuing to address the growing problem of myopia in children’’ said Griff Altmann, Chief Technology Officer at HOYA Vision Care. “We are very pleased to have the opportunity to share the latest clinical research data during the EAOO Helsinki 2021 conference.”

The virtual Myopia Symposium event on April 24 will be held from 10-11 a.m. local Helsinki time.

Click HERE for the full press release.

Novartis Pharmaceuticals Canada Helps Canadians with Sight Loss Face Challenges of COVID-19 Head On

CNIB thanks Novartis Pharmaceuticals Canada Inc. for their longstanding support of people with sight loss across the country.

Most recently, Novartis enabled a telephone outreach campaign to occur right when COVID-19 hit to make sure none of the CNIB participants was left behind. This involved calling more than 11,000 participants to check on their wellness and find out what support they needed.

Their generous support is also being invested in a program called Advocacy 2.0, which will help Canadians who are blind or partially sighted learn how to successfully self-advocate and stand up for their own rights.

Click HERE for the full press release.

Zyloware Announces the Promotion of Gilda Mehraban

Zyloware has announced the promotion of Gilda Mehraban to Vice President Corporate Accounts and Business Development. As part of the Global Sales team at Zyloware, Gilda will provide a focus on strategic opportunities within the United States and Canadian markets. In her time at Zyloware, Gilda has developed specialized expertise in key account and chain management with an eye on brand building.

Mehraban was previously the Director of Business Development for De Rigo REM, managing and developing the company’s key accounts channel of distribution across the U.S. and Canada.

Previously, Gilda was the Director of Business Affairs and Legal Counsel for CMG Worldwide, as an attorney focused on intellectual property protection and licensing. In that role, she was involved in marketing and creating licensing opportunities for approximately 200 entertainment, music, sports and historical properties, including Marilyn Monroe and James Dean.

Source: Zyloware

April 20, 2021May 19, 2026

Carl Zeiss Meditec Returns to Significant Revenue Growth in Second Quarter 2020/21

Carl Zeiss Meditec AG has achieved revenue of EUR 767.4 million in the first half of fiscal year 2020/21. This corresponds to a revenue development of +7.3% vs. the past year (after adjustment for currency effects: +10.5%). In the second quarter of FY 2020/21, revenue amounted to EUR 398.5 million – a growth rate of +15.4% (after adjustment for currency effects: +18.8%).

Earnings before interest and taxes (EBIT) amounted to EUR 162.7 million in the first half of FY 2020/21. EBIT margin (EBIT / revenue) was 21.2%. In the second quarter of FY 2020/21, EBIT amounted to EUR 89.3 million. EBIT margin was 22.4%.

Full results for the first half 2020/21 will be published on May 10, 2021.

During the further course of FY 2020/21, the company expects an ongoing normalization of business development. Revenue is expected to reach around EUR 1.6 billion in FY 2020/21. EBIT margin for FY 2020/21 is projected to reach a level of approximately 20%.

Click HERE for the full press release.

Other related news